Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pinocembrin Injection for Ischemic Stroke
NCT02059785Phase 2Suspended
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2013
- Primary completion
- Dec 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing Pinocembrin with Placebo (2 arms). Primary endpoint: Proportion of subjects with mRS score 0-1 at 90 days. Started Jun 2013; status: suspended.
02
Drugs
pinocembrin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02059785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02059785.